News

PATHFAST cTnI-II test should be used with the PATHFAST analysis system, a chemi-luminescence immunoanalyzer that measures concentrations of emergency biomarkers from a single whole blood sample. The test

The trial will assess patients with meniscal tears (injury to cartilage tissues in the knee joint). In the trial, the company plans to treat patients with a cell

Upon completion of the merger, Trimeris will issue to Synageva stockholders shares of Trimeris common stock such that Synageva stockholders will own 75% of the combined company’s shares

Indomethacin for injection is indicated to close a hemodynamically patent ductus arteriosus in premature infants, who typically have small blood vessels. The voluntary recall was initiated because some

Following the transaction, which is still subject to approval of Peoples Republic of China’s authorities, GSK will become the sole owner of GSKNB. With this acquisition, GSK intends

The Consent Decree is subject to approval by the US District Court in the Eastern District of Wisconsin. H&P has enlisted an independent expert who will inspect the

Easton will continue to serve as chairman of the board following the appointment of the company’s new CEO. He has spent the past eight years managing research projects

Orexo is planning to start and conclude the next clinical study in healthy volunteers in the fourth quarter of 2011. Orexo president and CEO Anders Lundstrom said OX27

The company’s decision follows two years of expansion and investment in a £15m laboratory in Cardiff. Quotient Bioresearch, a provider of early stage drug development services to pharmaceutical